Post on 02-Feb-2016
description
transcript
Global Review of Medicines Regulation: Current Highlights
and Future Trends
Dr Lembit Rägo Coordinator,
Quality Assurance and Safety: MedicinesMedicines Policy and Standards
World Health OrganizationE-mail: ragol@who.int
National Regulatory Conference 2005Kuala Lumpur, Malaysia
6 September 2005
2WHO - PSM
Content
Introductory remarks Global regulatory environment Harmonization New challenges and trends Role of WHO Challenges remaining
3WHO - PSM
SmellAppearance Taste
Medicines regulation: What is it all about?
Usual perceptions may not help in making judgements about medicines …
4WHO - PSM
Why Stringent Standards for Medicines?
Medicines are different from other goods as patients (consumers) and even health care professionals are not able to judge their "quality" or "fitness for use"
"… drugs are a public good and not simply just another commodity: first for their high social value, and then because consumers and prescribers are unable to assess their quality, safety and efficacy" (Dr Gro Harlem Brundtland, former Director General of the World Health Organization)
This is the reason why medicines belong to one of the most regulated group of products
5WHO - PSM
What Standards for Medicines?
Medicines must meet quality, safety and efficacy criteria.
These three sets of requirements are complementary to each other and each product has to be of good quality, safe and efficacious.
It is possible that a product is of good quality, but may not necessarily be effective or safe
It is possible that a product is effective, but may not necessarily be of good quality or safe
It is possible that a product is safe but may not be of good quality or effective
6WHO - PSM
What type of medicines we have? 1. Innovator products
For these products one has to prove their safety, efficacy and quality. Basis for these criteria is created by respective scientific disciplines. Implementation is executed through respective laws and regulations.
Proving safety and efficacy is the key for these products. It is based on the results of pre-clinical (i.e. animal toxicology) and clinical (clinical studies carried out in healthy volunteers and patients) research
Innovator (or originator) products New innovative products that nobody yet has marketed, usually
based on the new active ingredient (chemical compound which is responsible for its effects in human subjects)
The manufacturer has also to prove that its processes to produce the product and methods invented to control its quality are meeting established quality requirements.
7WHO - PSM
Who sets the scene for regulating innovator products?
8WHO - PSM
International Conference on Harmonisation of Technical Requirements for Registrationof Pharmaceuticals for Human Use
Six Co-sponsors - members of Steering Committee
European Commission EC
European Federation of PharmaceuticalIndustry Associations EFPIA
Japanese Ministry of Health and Welfare MHW
Japanese Pharmaceutical Manufacturers Association JPMA
US Food and Drug Administration FDA
Pharmaceutical Manufacturers Association PhRMA
9WHO - PSM
ICH Steering Committee Observers
World Health Organization (WHO)
Canada - Health Protection Branch
European Free Trade Area (EFTA)
10WHO - PSM
ICH SC latest press release 2005
11WHO - PSM
ICH Global Cooperation Group (GCG)
12WHO - PSM
ICH Global Cooperation Group (GCG) - challenges
Very different by composition (countries with very different level of socioeconomic development) and objectives regional harmonization initiatives
Often in some countries indirectly involved ABC not yet fixed whereas other countries may have much higher levels of development
Relatively low level of resource investments available in harmonization as compared to ICH
Some may more have interest in regulating generic medicines well first (but this is not exactly ICH objective)
13WHO - PSM
How can non-ICH countries benefit from ICH products? Challenges for policy makers
Priority setting (ABC first) … may be long way to go Real control of market, functional DRA and inspectorate Basic quality assurance measures like GMP, etc. If market 90 % generics, regulate well generics first … Implementation of ICH products vs recognition of
registrations based on ICH guidelines? Availability of resources
What is the cost of implementation of ICH guidelines and training?
What is the minimum number of regulators needed to assess a new drug according to ICH guidelines
Step-by-step approach
14WHO - PSM
Where are we going with innovation?
Do we need new medicines? Which type of new medicines we need? What needs to be done to get new medicines out?
Is increase of spending on R&D the only solution? What about new medicines for public health needs? What can regulators do?
15WHO - PSM
New initiatives to streamline drug approval process
16WHO - PSM
Research spending
17WHO - PSM
… and product submissions to FDA
18WHO - PSM
Increase in certain segments of development costs
19WHO - PSM
Project Failure is Highest in Phase II
CMR data based on cohort approach looking at fate of NCEs entering phase 1996-1998, with progression decision made by 2001*
*adapted from Ashton GA, Joshua PJ. Industry success rates 2002. CMR International Ltd
Mea
n P
rob
abil
ity
Of
Su
cces
s O
f C
om
ple
tin
g S
tag
e P
oS 66%
37%
57%
79%
11%
14 mnths$40m
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
Phase I Phase II Phase III File and Launch Phase I to Launch
20 mnths$40m
28 mnths$160m
20WHO - PSM
Three dimensions of Critical Path
21WHO - PSM
Poorly developed areas – Paediatric medicines
Paediatric indications based on evidence – only approximately 50% of use has backing by clinical research
Incentives for paediatric research created in several countries (exclusivity rights increased etc.) US EU
Not much specific regulatory guidance Lack of paediatric formulations needed – ARVs
22WHO - PSM
Recent safety concerns and withdrawals – COX2 inhibitors in focus
Are regulatory models used to assess safety appropriate? Independence of pharmacovigilance from authorization
staff US Congress interested and investigates issues
Can safety be predicted in a better manner? Are new regulatory guidance documents needed?
23WHO - PSM
Pharmacogenetics (PGx): significant potential to address some of the challenges
Pharmaceutical companies and regulators are actively exploring PGx applications. Draft guidance issued by some regulators, discussions in ICH environment
CIOMS report “Impact of Pharmacogenetics on Drug Discovery and Development,”
key development drivers and hurdles relevant to the implementation of PGx in drug development
the potential role PGx may play in the drugdevelopment process
24WHO - PSM
New regulatory pathways to assure quality, safety and efficacy of medicines for public health needs in developing world
WHO Prequalification Program
US FDA tentative approval process for ARVs
EU Article 58 process
25WHO - PSM
WHO Prequalification
The UN prequalification program is an action plan for
expanding access to medicines for the hardest hit by
HIV/AIDS
Tuberculosis
Malaria
by ensuring quality, efficacy and safety of medicines
procured using international funds
26WHO - PSM
Why the prequalification is needed?
Problems• Millions of people living with HIV/AIDS, tuberculosis and
malaria, have no or limited access to treatment• Substandard products widely available and in circulation• Weak/absent QA systems of medicines supply chain• Lot of money invested in procurement
no harmonized quality assurance system available for procurement organizations/initiatives
Risks• Sourcing of poor quality products or even counterfeit
medicines risk to patients, treatment failure, resistance
27WHO - PSM
Prequalification basic principles
Rigour regulatory approach to ensure quality, safety and efficacy Voluntary for participating manufacturers Legitimate - General procedure and standards approved through
WHO Expert Committee system involving all WHO Member States and WHO Governing bodies
Widely discussed • FIP Congress, Nice 2002 • Supported by ICDRA in 2002 and 2004, representing more than
100 national drug regulatory authorities Transparent (all information available on the web site
http://www.who.int/medicines/) Open to both innovators and multisource/generic manufacturers No cost for applicants (manufacturers) during pilot phase
28WHO - PSM
Prequalification: misunderstandings and critics
Too high standards increasing prices … Too high and unnecessary standards for developing
countries … Too bureaucratic and slow, not proactive and not able to
provide products…
Too low standards …. " This leaves the impression with readers that the ARVs
approved by WHO are in fact generic products that are interchangeable with their innovator cousins. From available documents, however, we conclude that they are copy products with unknown quality, safety and efficacy profiles".
29WHO - PSM
How prequalification is organized
Role of WHO: Managing and organizing the project on behalf of the United Nations.
• provide technical and scientific support and guarantee that international norms and standards are applied all through the process including assessment, inspection (GMP, GCP, GLP) and quality control
Partners: • UNICEF, UN Population Fund (UNFPA), UNAIDS and with the
support of the World Bank• Anti-malarial and anti-TB products: Roll Back Malaria and Stop TB
(Global Drug Facility) Actors: Mainly assessors and inspectors of National DRAs as
well as National Quality Control Laboratories of PIC/S and ICH member countries
30WHO - PSM
Assessment procedure
I. Assessment of products dossiers i.e. quality specifications, pharmaceutical development, bioequivalence etc. teams of professionals from national drug regulatory authorities (DRA): Brazil,
Canada, Denmark, Estonia, Finland, France, Germany, Hungary, Indonesia, Malaysia, Philippines, Spain, South-Africa, Sweden, Switzerland, Tanzania, UK, Zimbabwe ...
II. Inspections Manufacturing site (final product, packaging) Active pharmaceutical ingredient (API) Research laboratory or Contract Research Organization (CRO) Teamwork of inspectors
• WHO representative (qualified GMP inspector)• Inspector from well-established inspectorate (Pharmaceutical Inspection
Convention Scheme countries): Australia, Canada, UK, France, Italy, Switzerland, …
Quality control analysis - upon need but not always necessarily before prequalification and supply, increasingly as part of follow-up
31WHO - PSM
Current status – 2005
Started with HIV/AIDS products in 2001 – malaria and TB products joined later
Prequalified products Submitted • 95 HIV related medicines - 289• 8 anti-tuberculosis medicines - 153• 2 anti-malarial medicines - 46 • 105 488
Ongoing assessments and follow-up• Products• Manufacturing sites • CROs
32WHO - PSM
Ongoing monitoring and requalification
Samples taken after supply Routine inspections and additional inspections Changes and variations controlled
• Products and manufacturers Requalification (re-assessment) every 3 years World Health Assembly resolution: WHA57.14 of May 2004
• Public reports • WHO Public Assessment Report (WHOPAR)• WHO Public Inspection Report (WHOPIR)
33WHO - PSM
Prequalification
Good news Relatively large number of products and suppliers indicated Many potential suppliers appreciating feedback and willing to improve Unique knowledge obtained about generic products De-listed products coming back to the prequalified products list
Bad news Only limited number of products have met the required standards A number of de-listings from the prequalified products list in 2004 Takes time to get into compliance
• Data to be generated, tests carried out• GMP upgrade needed
Bad quality generics may undermine the public confidence in generics Quality assurance has its price!
34WHO - PSM
Lessons to be learned
Quality can not be assessed, tested or inspected into the product, BUT
It has to be built into it!
35WHO - PSM
http://mednet3.who.int/prequal/
36WHO - PSM
37WHO - PSM
US FDA tentative approvals
Exactly the same standards for assessment as for US internal market
The same inspection standards The same post approval surveillance When IP rights allow (patents and other exclusivity rights)
can enter US market
Limited to ARVs as linked to specific program – does not cover other product groups
38WHO - PSM
Article 58: LEGAL BASIS AND SCOPE
Article 58 of Regulation (EC) No 726/20041 (“the Regulation”) establishes a mechanism whereby the European Medicines Agency (EMEA) may give a scientific opinion, in the context of cooperation with the World Health Organization (WHO), for the evaluation of certain medicinal products for human use intended exclusively for markets outside the Community.
The Committee for Medicinal Products for Human Use may, after consulting the World Health Organization, draw up a scientific opinion in accordance with Articles 6 to 9.
39WHO - PSM
40WHO - PSM
Article 58 – Why? Under new EU legislation the EU Commission will no longer license
medicinal products unless they are to be placed on the market in the EU.
Applicants were not able to get marketing authorization in the EU for products that had no market
WHO CPPs not issued under such circumstances – no basis for acceptance by other DRAs
Commission did not intend to kill incentives from companies to address public health issues outside the EU
41WHO - PSM
How Article 58 will work?
Strong cooperation with the WHO WHO gate keeper (determines if product is of high public health
value) WHO can send observers to CHMP WHO can provide experts to EMEA
Procedure resembles centralized procedure – same standards
Outcome not MA but "scientific opinion for WHO" WHO type CPP will be issued EPAR like document will be made public
42WHO - PSM
Specific non-EU medical needs
Medicines for non-EU use only due to - Specific epidemiological situation
- Specific socio-economical conditions- Specific logistical conditions
Vaccine examples:- Pneumococcal vaccines with adapted
composition- Multidoses containing thiomersal etc.
43WHO - PSM
44WHO - PSM
What type of medicines we have?
2. Generic products
The term generic product has somewhat different meanings in different jurisdictions. Therefore, term multisource pharmaceutical product is preferred by WHO.
Where the term generic product is used, it means a pharmaceutical product, usually intended to be interchangeable with the innovator product, which is usually manufactured without a license from the innovator company and marketed after expiry of the patent or other (e.g. data) exclusivity rights.
Multisource pharmaceutical (generic) products are pharmaceutically equivalent products that may or may not be therapeutically equivalent. Multisource pharmaceutical products that are therapeutically equivalent are interchangeable
45WHO - PSM
What standards are need for generic medicines?
For generic medicines the manufacturer has to prove that the product meets all quality requirements
In case of safety and efficacy it refers to the originator's research
To prove the therapeutic interchangeability it has, as a rule, to carry out bioequivalence studies (small scale clinical trials in healthy volunteers to examine if the test drug has essentially the same blood concentration pattern of active ingredient as the originator.
It is assumed that if the blood concentrations are essentially the same the safety and efficacy profile is also the same.
46WHO - PSM
Standards for generic drugs: first priority
WHO continues to issue Global standards for generic medicines and regulatory topics for public health importance
47WHO - PSM
39th WHO Expert Committee on Specifications for Pharmaceutical Preparations, 25-29 October 2004 (I)
Draft Guidelines FDC -WHO-QAS04_108 (Fixed Dose Combination guidelines) GMP_Herbal_RevJuly-04_QAS050 Interchangeability-WHO-QAS_093Rev3_23Sept04 (bioequivalence) QAS_055_Rev1_validation (supplementary to GMP) QAS_066_Rev3_sampling (to replace 1990 guideline) QAS_068_GDP – see next slide for details QAS047_Rev1_Water (GMP) Guidelines on MP HVAC (Rev 4) (GMP; Heating, ventilation and air
conditioning for non-sterile dosage forms)
http://www.who.int/medicines/organization/qsm/expert_committee/expertcomm.shtml
48WHO - PSM
49WHO - PSM
What is WHO doing in order to reduce quality and regulatory gaps?
Assessing regulatory capacity upon request Supporting capacity building and training of regulators
Issuing norms and standards and guidance materials Preparing training tools, organizing training seminars and workshops
on variety of topics as requested by countries - GMP, MA of Generic Drugs, GCP, GLP, Pharmacovigilance etc.
Facilitating information exchange Supporting regional harmonization initiatives
Favoring networking and cooperation Providing technical assistance upon request
Ultimate goal: improve access to quality drugs for all citizens
50WHO - PSM
International Conference of Drug Regulatory Authorities
Biennial unique forum of regulators Brings together more than 100 countries
51WHO - PSM
Information exchange.WHO Drug Informationhttp://www.who.int/druginformation/
52WHO - PSM
SUnfinished agendas:
1. In many countries ABC recommendations of this document to implement effective drug regulation of medicines are still not implemented
53WHO - PSM
2.Unregulated online shopping: threat for public health
54WHO - PSM
3. Counterfeit medicines: Global threat to public health
55WHO - PSM
3. Counterfeit medicines: no country is immune
Figure 1. The Number of Investigations of possible counterfeit drugs by the FDA has been rising(Figure: Margaret Shear, Public Libraryof Science, cited form Cockburn R, Newton PN, Agyarko EK, Akunyili D, White NJ (2005) PLoS Med 2(4): e100.
56WHO - PSM
As health professionals, in public and private sector, as an international community
...we have a lot left to do …all of us, together, things that do matter,
in right time and in right order
www.who.int/medicines